T lymphocyte subset imbalances in patients contribute to ankylosing spondylitis

Chenggong Wang, Qiande Liao, Yihe Hu, DA Zhong, Chenggong Wang, Qiande Liao, Yihe Hu, DA Zhong

Abstract

Ankylosing spondylitis is a chronic inflammatory rheumatic disease, which is characterized by inflammation of the spine and the sacroiliac joints. To date, the disease etiology remains unclear. In the present study, the correlation of T lymphocyte subset changes with the progression of ankylosing spondylitis was investigated. A total of 55 patients with ankylosing spondylitis (22 severe and 23 mild cases) and 20 healthy individuals were selected. Firstly, the punctured cells in the lesions and the serum were collected, and the lymphocytes and the peripheral blood mononuclear cells were prepared. Secondly, quantitative PCR, ELISA and flow cytometry analyses were carried out to detect the levels of a series of immunoglobulins, complements, helper T cells, cytotoxic T cells, regulatory cells and cytokines. The expression levels of α-globulin, γ-globulin, immunoglobulin (Ig)G, IgA, IgM, serum complement C3, and complement C4 were found to be significantly increased in ankylosing spondylitis patients. In addition, the percentage of Th1 and Th17 cells was found to be significantly higher in the ankylosing spondylitis groups (mild and severe) compared with the healthy individuals. As a result, the Th1/Th2 and Th17/Treg ratios were significantly higher in patients with ankylosing spondylitis. In addition, T lymphocyte subset ratio imbalances contributed to an increased expression of immune mediators, including interferon (IFN)-γ and interleukin (IL)-17A. The mRNA and protein expression levels of IFN-γ and IL-17A were found to be higher in the ankylosing spondylitis groups compared with the control group. The present study provided further evidence on the function and underlying mechanism of T lymphocyte subsets, which may be useful in the diagnosis and treatment of ankylosing spondylitis.

Keywords: T lymphocyte subsets; ankylosing spondylitis; cytokines; imbalance; inflammation.

Figures

Figure 1
Figure 1
Changes in (A) the percentage of CD3+, CD3+CD8− and CD3+CD8+ cells and (B) the CD3+CD8−/CD3+CD8+ ratio among the control, mild ankylosing spondylitis and severe ankylosing spondylitis groups.
Figure 2
Figure 2
Th1/Th2 and Tc1/Tc2 ratio imbalance in patients with ankylosing spondylitis. The percentages of (A) Th1 and (B) Th2 cells, (C) Th1/Th2 ratio, percentages of (D) Tc1 and (E) Tc2 cells and (F) Tc1/Tc2 ratio are shown for the control, mild ankylosing spondylitis and severe ankylosing spondylitis groups. Different letters indicate a significant difference among the groups (P

Figure 3

Percentages of (A) Tc17, (B)…

Figure 3

Percentages of (A) Tc17, (B) Th17 and (C) Treg cells, as well as…

Figure 3
Percentages of (A) Tc17, (B) Th17 and (C) Treg cells, as well as (D) the Th17/Treg ratio, are shown for the control, mild ankylosing spondylitis and severe ankylosing spondylitis groups. Different letters indicate a significant difference among the groups (P

Figure 4

Relative mRNA and protein expression…

Figure 4

Relative mRNA and protein expression levels of (A) IFN-γ, (B) IL-17A, (C) IL-4…

Figure 4
Relative mRNA and protein expression levels of (A) IFN-γ, (B) IL-17A, (C) IL-4 and (D) TGF-β are shown for the control, mild ankylosing spondylitis and severe ankylosing spondylitis groups. Different letters indicate a significant difference among the groups (P
Similar articles
Cited by
References
    1. Calin A, Porta J, Fries JF, Schurman DJ. Clinical history as a screening test for ankylosing spondylitis. JAMA. 1977;237:2613–2614. doi: 10.1001/jama.1977.03270510035017. - DOI - PubMed
    1. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379–1390. doi: 10.1016/S0140-6736(07)60635-7. - DOI - PubMed
    1. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatology. 1997;36:766–771. doi: 10.1093/rheumatology/36.7.766. - DOI - PubMed
    1. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–368. doi: 10.1002/art.1780270401. - DOI - PubMed
    1. Graham B, Van Peteghem PK. Fractures of the spine in ankylosing spondylitis. Diagnosis, treatment, and complications. Spine (Phila Pa 1976) 1989;14:803–807. doi: 10.1097/00007632-198908000-00005. - DOI - PubMed
Show all 36 references
Related information
Full text links [x]
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Follow NCBI
Figure 3
Figure 3
Percentages of (A) Tc17, (B) Th17 and (C) Treg cells, as well as (D) the Th17/Treg ratio, are shown for the control, mild ankylosing spondylitis and severe ankylosing spondylitis groups. Different letters indicate a significant difference among the groups (P

Figure 4

Relative mRNA and protein expression…

Figure 4

Relative mRNA and protein expression levels of (A) IFN-γ, (B) IL-17A, (C) IL-4…

Figure 4
Relative mRNA and protein expression levels of (A) IFN-γ, (B) IL-17A, (C) IL-4 and (D) TGF-β are shown for the control, mild ankylosing spondylitis and severe ankylosing spondylitis groups. Different letters indicate a significant difference among the groups (P
Similar articles
Cited by
References
    1. Calin A, Porta J, Fries JF, Schurman DJ. Clinical history as a screening test for ankylosing spondylitis. JAMA. 1977;237:2613–2614. doi: 10.1001/jama.1977.03270510035017. - DOI - PubMed
    1. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379–1390. doi: 10.1016/S0140-6736(07)60635-7. - DOI - PubMed
    1. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatology. 1997;36:766–771. doi: 10.1093/rheumatology/36.7.766. - DOI - PubMed
    1. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–368. doi: 10.1002/art.1780270401. - DOI - PubMed
    1. Graham B, Van Peteghem PK. Fractures of the spine in ankylosing spondylitis. Diagnosis, treatment, and complications. Spine (Phila Pa 1976) 1989;14:803–807. doi: 10.1097/00007632-198908000-00005. - DOI - PubMed
Show all 36 references
Related information
Full text links [x]
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM
Figure 4
Figure 4
Relative mRNA and protein expression levels of (A) IFN-γ, (B) IL-17A, (C) IL-4 and (D) TGF-β are shown for the control, mild ankylosing spondylitis and severe ankylosing spondylitis groups. Different letters indicate a significant difference among the groups (P

References

    1. Calin A, Porta J, Fries JF, Schurman DJ. Clinical history as a screening test for ankylosing spondylitis. JAMA. 1977;237:2613–2614. doi: 10.1001/jama.1977.03270510035017.
    1. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379–1390. doi: 10.1016/S0140-6736(07)60635-7.
    1. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatology. 1997;36:766–771. doi: 10.1093/rheumatology/36.7.766.
    1. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–368. doi: 10.1002/art.1780270401.
    1. Graham B, Van Peteghem PK. Fractures of the spine in ankylosing spondylitis. Diagnosis, treatment, and complications. Spine (Phila Pa 1976) 1989;14:803–807. doi: 10.1097/00007632-198908000-00005.
    1. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359:1187–1193. doi: 10.1016/S0140-6736(02)08215-6.
    1. Akhtar S, O’Flynn PE, Kelly A, Valentine PM. The management of dysphasia in skeletal hyperostosis. J Laryngol Otol. 2000;114:154–157. doi: 10.1258/0022215001904950.
    1. Imhof H, El-Khoury GY. Musculoskeletal Diseases. Springer; Milan: 2005. Traumas of the Axial Skeleton; pp. 112–120.
    1. Van der Linden SM, Valkenburg HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum. 1984;27:241–249. doi: 10.1002/art.1780270301.
    1. Brown MA, Kennedy LG, MacGregor AJ, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum. 1997;40:1823–1828. doi: 10.1002/art.1780401015.
    1. Jacobs JC, Berdon WE, Johnston AD. HLA-B27-associated spondyloarthritis and enthesopathy in childhood: clinical, pathologic, and radiographic observations in 58 patients. J Pediatr. 1982;100:521–528. doi: 10.1016/S0022-3476(82)80746-4.
    1. Leirisalo-Repo M. Reactive arthritis. Scand J Rheumatol. 2005;34:251–259. doi: 10.1080/03009740500202540.
    1. Atagunduz P, Appel H, Kuon W, et al. HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. Arthritis Rheum. 2005;52:892–901. doi: 10.1002/art.20948.
    1. Braun J, Khan MA, Sieper J. Enthesitis and ankylosis in spondyloarthropathy: what is the target of the immune response? Ann Rheum Dis. 2000;59:985–994. doi: 10.1136/ard.59.12.985.
    1. Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 2000;43:1346–1352. doi: 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>;2-E.
    1. Reinherz EL, Schlossman SF. The differentiation and function of human T lymphocytes. Cell. 1980;19:821–827. doi: 10.1016/0092-8674(80)90072-0.
    1. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708–712. doi: 10.1038/44385.
    1. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev. 1996;9:532–562.
    1. Wilke CM, Bishop K, Fox D, Zou W. Deciphering the role of Th17 cells in human disease. Trends Immunol. 2011;32:603–611. doi: 10.1016/j.it.2011.08.003.
    1. Yen HR, Harris TJ, Wada S, et al. Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol. 2009;183:7161–7168. doi: 10.4049/jimmunol.0900368.
    1. Szalay B, Mészáros G, Cseh Á, et al. Adaptive immunity in ankylosing spondylitis: phenotype and functional alterations of T-cells before and during infliximab therapy. Clin Dev Immunol. 2012;2012:808724. doi: 10.1155/2012/808724.
    1. Raffeiner B, Dejaco C, Duftner C, et al. Between adaptive and innate immunity: TLR4-mediated perforin production by CD28null T-helper cells in ankylosing spondylitis. Arthritis Res Ther. 2005;7:R1412–R1420. doi: 10.1186/ar1840.
    1. Lin Q, Gu JR, Li TW, et al. Value of the peripheral blood B-cells subsets in patients with ankylosing spondylitis. Chin Med J (Eng) 2009;122:1784–1789.
    1. Wu Y, Ren M, Yang R, et al. Reduced immunomodulation potential of bone marrow-derived mesenchymal stem cells induced CCR4+CCR6+ Th/Treg cell subset imbalance in ankylosing spondylitis. Arthritis Res Ther. 2011;13:R29. doi: 10.1186/ar3257.
    1. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev. 2003;8:223–246.
    1. Yao S, Hong CC, McCann SE, et al. Combined effects of circulating levels of 25-hydroxyvitamin d and Th1 and th2 cytokines on breast cancer estrogen receptor status. Cancers (Basel) 2014;6:211–225. doi: 10.3390/cancers6010211.
    1. Hou N, Zhang X, Zhao L, et al. A novel chronic stress-induced shift in the Th1 to Th2 response promotes colon cancer growth. Biochem Biophys Res Commun. 2013;439:471–476. doi: 10.1016/j.bbrc.2013.08.101.
    1. Gut W, Pancer K, Abramczuk E, et al. RSV respiratory infection in children under 5 y.o - dynamics of the immune response Th1/Th2 and IgE. Przegl Epidemiol. 2013;67:17–22.
    1. Vitry MA, De Trez C, Goriely S, et al. Crucial role of gamma interferon-producing CD4+ Th1 cells but dispensable function of CD8+ T cell, B cell, Th2, and Th17 responses in the control of Brucella melitensis infection in mice. Infect Immun. 2012;80:4271–4280. doi: 10.1128/IAI.00761-12.
    1. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007;13:139–145. doi: 10.1038/nm1551.
    1. Yasukawa S, Dainichi T, Kokuba H, et al. Bullous pemphigoid followed by pustular psoriasis showing Th1, Th2, Treg and Th17 immunological changes. Eur J Dermatol. 2009;19:69–71.
    1. Bryant C, Suen H, Brown R, et al. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J. 2013;3:e148. doi: 10.1038/bcj.2013.34.
    1. Gaur P, Qadir GA, Upadhyay S, Singh AK, Shukla NK, Das SN. Skewed immunological balance between Th17 (CD4(+)IL17A (+)) and Treg (CD4 (+)CD25 (+)FOXP3 (+)) cells in human oral squamous cell carcinoma. Cell Oncol (Dordr) 2012;35:335–343. doi: 10.1007/s13402-012-0093-5.
    1. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev. 2008;226:57–79. doi: 10.1111/j.1600-065X.2008.00699.x.
    1. Cañete JD, Martínez SE, Farrés J, et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann Rheum Dis. 2000;59:263–268. doi: 10.1136/ard.59.4.263.
    1. Rudwaleit M, Haibel H, Baraliakos X, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009;60:717–27. doi: 10.1002/art.24483.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit